Newsletter · · Ashutosh Agarwal

Medicare Premiums Climb and Lilly Leans On Its GLP-1 Engine - Healthcare Policy: Drug Pricing, IRA & Managed Care - Week of August 29, 2026

Healthcare Policy: Drug Pricing, IRA & Managed Care for the week of August 22 to 29, 2026. A front-line Medicare agent explains why Medigap Plan G premiums are rising faster than anyone budgeted for, Fidelity pegs lifetime retirement healthcare costs at roughly $185,500 per person, and Eli Lilly lifts full-year revenue guidance to $85 to $87 billion on continued GLP-1 strength.

Healthcare Policy: Drug Pricing, IRA & Managed Care

Week of August 29, 2026: Medicare Premiums Climb and Lilly Leans On Its GLP-1 Engine

Intro

The loudest healthcare-money signals this week did not come out of Washington's marquee drug-pricing fights. They came from the two ends most people actually feel: the kitchen table, where Medicare premiums are climbing faster than anyone budgeted for, and the boardroom, where Eli Lilly is spending a GLP-1 windfall on a second act. Both stories tell you the same thing from opposite directions. The cost of care keeps grinding higher, and the whole system is scrambling to figure out who pays for it.

Here is the useful part: a front-line Medicare agent walked through, in plain numbers, exactly why premiums are jumping, and it is the same medical cost trend force that squeezes every big health insurer. Let's start there.

TL;DR

  • Medicare supplement premiums, especially the popular "Plan G," are rising faster than expected, because the pool of people in that plan keeps growing and aging, and their medical claims keep climbing. It is a real-world read on the same rising-cost, rising-usage pressure that hits every health insurer's margins. (Talk Money with Jim Shoemaker)
  • A 65-year-old retiring in 2026 should plan for roughly $185,500 in lifetime healthcare costs, per person, and most Americans are budgeting for less than half of that. That is before any long-term care. (Talk Money, citing Fidelity)
  • Eli Lilly raised its full-year revenue guidance to roughly $85 to $87 billion on continued Mounjaro and Zepbound strength, and is putting that cash to work diversifying beyond obesity and diabetes. The takeaway: the GLP-1 business is throwing off enough cash to fund a whole new act. (Telltales)

What's new

1. "Plan G" sticker shock, and the plumbing behind it. Claire Green, a working Medicare supplement agent (a front-line operator, not a commentator), laid out why so many retirees are opening renewal letters in shock. Medicare supplement plans, often called "Medigap," are the private insurance that fills the gaps in traditional Medicare, and they are getting more expensive every year. Plan G, currently the most popular option, is leading the increases.

"Unfortunately, Medicare supplement products are not immune to these rising costs that we're seeing in other industries. And those premiums are climbing each year… Particularly in the last 24 months, Plan G increases year over year have increased higher than anyone anticipated."

The reason is a slow-motion demographic squeeze. Back in January 2020, insurers stopped selling the old gold-standard plan, "Plan F," to new retirees. Everyone turning 65 after that funneled into Plan G instead. Six-plus years later, that Plan G pool is huge, and aging:

"That risk pool enrolled in G is incurring higher total claims year after year."

A "risk pool" is simply the group of people covered by a plan. As that group gets older and sicker, its total medical bills rise, and insurers pass the cost back as higher premiums. Why it matters: this is the clearest possible ground-level confirmation that medical cost trend is still running hot, the exact force that has been pressuring Medicare Advantage insurers' profits (Talk Money with Jim Shoemaker, Aug 22).

2. The trade-down to "Plan N." As Plan G premiums bite, Green says more retirees are switching to the cheaper Plan N. The trade-off is that Plan N makes you pay small charges each time you use care:

"With Plan N, we still have to meet that Part B deductible. But in addition to that, you're going to have co-pays for office visits and emergency room visits. So it's going to be a $20 co-pay for any and all doctor visits… And $50 co-pay for emergency room visits."

(The Part B deductible, the amount you pay before coverage kicks in, is $283 this year.) Why it matters: when consumers start trading down to plans with usage-based charges, that is a demand signal worth watching. It is the retiree version of the same buy-down behavior insurers and employers use when medical costs get uncomfortable (Talk Money with Jim Shoemaker, Aug 22).

3. The retirement healthcare bill nobody is budgeting for. Citing Fidelity's annual estimate, the show flagged that a 65-year-old retiring in 2026 should expect to spend about $185,500 on healthcare over retirement, per person, roughly $370,000 for a couple, and crucially, that figure excludes long-term care. The gap between reality and expectation is stark:

"Americans today are not looking at that $185,000, which is projected costs. They're looking at a $75,000 understanding. So we're talking about $100,000 shortfall."

On the underlying inflation rate, the hosts pegged healthcare cost growth at "about a 5% increase… for the last several years," and framed the whole thing bluntly: healthcare is "not just an expense… it's really a retirement liability." Why it matters: the roughly 5% medical-inflation number is the drumbeat behind everything else in this newsletter. Medigap premiums, insurer margins, and drug pricing all trace back to it (Talk Money with Jim Shoemaker, Aug 22).

4. Lilly's GLP-1 engine funds the next act. This item comes from Telltales, an AI-generated markets podcast, so treat it as commentary rather than insider reporting, and note that we have dropped several of its Lilly claims that did not survive a date check. What does hold up is the guidance: Lilly raised its full-year revenue outlook to roughly $85 to $87 billion, on continued Mounjaro and Zepbound strength, and is directing that cash toward vaccines, infectious disease, and cancer partnerships to reduce its dependence on a single drug class.

The host's framing captured the strategic point better than any single number:

"That's Lilly buying a second act while GLP-1 is still paying for everything."

They put Lilly's trailing free cash flow at roughly $21 billion, with the stock carried at 58 times trailing free cash flow. (Free cash flow is the cash a business generates after paying its bills and investments, the money it can actually spend on deals or buybacks.) Why it matters: it is a vivid illustration of the GLP-1 gold rush. Lilly's obesity and diabetes franchise is cash-rich enough to finance a diversification push into vaccines and cancer, a hedge against the day GLP-1 growth slows or pricing pressure arrives (Telltales, Weekend Update W2634, Aug 23).

The debate

Is rising medical cost a temporary catch-up or a structural step-up? The Medigap story steel-mans both sides. The optimistic read: premiums are simply catching up to a post-pandemic cost bulge, and once pricing resets, the increases moderate. The pessimistic read, and the one the front-line evidence leans toward, is structural. An aging risk pool plus "cost of claims… increasing more than they've anticipated year over year" is not a one-time reset, it is a treadmill. If the person selling these plans every day is surprised by the size of the increases, insurers pricing Medicare Advantage and commercial plans are wrestling with the same math (Talk Money with Jim Shoemaker, Aug 22).

On Lilly, what is the market actually pricing? The bull case, as Telltales framed it: the GLP-1 engine keeps funding an expansion into new categories, reducing single-drug dependence over time, and the guidance raise says the engine is still accelerating. The bear case sits inside the same numbers. At roughly 58 times free cash flow, the valuation leaves little room for GLP-1 competition or future price cuts, and until the second act is real, the entire company still rides one drug class. As the host put it, the pivot is the tell: "only one of those [deals] is going to be visible a few years out" (Telltales, Weekend Update W2634, Aug 23).

The names in play

  • Eli Lilly (LLY) is the clearest name discussed this week: a guidance raise to $85 to $87 billion and a deliberate, cash-funded push into vaccines and infectious disease to diversify away from GLP-1 dependence. (Telltales)
  • Novo Nordisk (NVO), by read-through. Lilly's "GLP-1 is paying for everything" framing applies to the whole obesity-drug complex: the same cash engine, and the same eventual question of how durable the pricing and growth are. (inferred from Telltales' GLP-1 discussion)
  • Medigap and Medicare Advantage carriers were not named individually, but the premium-increase and rising-claims commentary reads directly onto the large managed-care insurers. (Talk Money)

Read-throughs

  • Managed care and Medicare Advantage insurers (UNH, HUM, ELV, CVS, CNC, MOH, CI): the Medigap premium spike and the "claims increasing more than anticipated" comment are a front-line echo of the medical cost trend that has hammered MA margins. When even supplemental-plan pricing is surprising to the pros, it argues the utilization and cost pressure on managed care has not fully cooled. (Talk Money)
  • GLP-1 exposure (employers, PBMs, insurers): Lilly's cash flood is the mirror image of everyone else's cost problem. The money funding Lilly's shopping spree is coming out of health plans' and employers' budgets. The bigger GLP-1 gets for Lilly, the bigger the coverage-cost debate gets for the payers. (Telltales)
  • Pharma strategy and drug pricing: Lilly using peak cash flow to buy future revenue streams is the classic move of a pharma company preparing for eventual pricing and patent pressure. Nothing this week named the IRA or the 2028 negotiation list directly, but the diversification instinct is exactly what that policy backdrop rewards. (Telltales)